Published in Blood on December 06, 2013
The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors. Endocr Relat Cancer (2014) 1.52
A Class of Environmental and Endogenous Toxins Induces BRCA2 Haploinsufficiency and Genome Instability. Cell (2017) 1.44
Deubiquitinases Modulate Platelet Proteome Ubiquitination, Aggregation, and Thrombosis. Arterioscler Thromb Vasc Biol (2015) 1.39
Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy. BMC Biol (2014) 1.29
SCF ubiquitin ligase-targeted therapies. Nat Rev Drug Discov (2014) 1.25
Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth. Oncotarget (2014) 1.08
Targeting the ubiquitin pathway for cancer treatment. Biochim Biophys Acta (2014) 0.93
Simultaneous inhibition of deubiquitinating enzymes (DUBs) and autophagy synergistically kills breast cancer cells. Oncotarget (2015) 0.90
Disassembly of Lys11 and mixed linkage polyubiquitin conjugates provides insights into function of proteasomal deubiquitinases Rpn11 and Ubp6. J Biol Chem (2014) 0.89
Synthesis and Evaluation of Derivatives of the Proteasome Deubiquitinase Inhibitor b-AP15. Chem Biol Drug Des (2015) 0.89
Promising therapies in multiple myeloma. Blood (2015) 0.89
Ubiquitin-specific protease 14 regulates c-Jun N-terminal kinase signaling at the neuromuscular junction. Mol Neurodegener (2015) 0.89
The 26S proteasome is a multifaceted target for anti-cancer therapies. Oncotarget (2015) 0.88
Usp5 links suppression of p53 and FAS levels in melanoma to the BRAF pathway. Oncotarget (2014) 0.87
Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cells. Br J Haematol (2015) 0.85
Molecular mechanisms in multiple myeloma drug resistance. J Clin Pathol (2015) 0.82
CDDO-Me reveals USP7 as a novel target in ovarian cancer cells. Oncotarget (2016) 0.81
JNK-NQO1 axis drives TAp73-mediated tumor suppression upon oxidative and proteasomal stress. Cell Death Dis (2014) 0.81
Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo. Oncotarget (2016) 0.80
Targeting proteasome ubiquitin receptor Rpn13 in multiple myeloma. Leukemia (2016) 0.80
Deubiquitinases (DUBs) and DUB inhibitors: a patent review. Expert Opin Ther Pat (2015) 0.79
Progress and Paradigms in Multiple Myeloma. Clin Cancer Res (2016) 0.78
Deubiquitinases in cancer. Oncotarget (2015) 0.78
Allosteric Activation of Ubiquitin-Specific Proteases by β-Propeller Proteins UAF1 and WDR20. Mol Cell (2016) 0.78
Inhibitory effect of b-AP15 on the 20S proteasome. Biomolecules (2014) 0.77
The Proteasome Ubiquitin Receptor hRpn13 and Its Interacting Deubiquitinating Enzyme Uch37 Are Required for Proper Cell Cycle Progression. J Biol Chem (2016) 0.77
A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy. Oncogene (2016) 0.77
USP14 is a predictor of recurrence in endometrial cancer and a molecular target for endometrial cancer treatment. Oncotarget (2016) 0.77
Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells. Blood Cancer J (2016) 0.77
The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells. Sci Rep (2016) 0.77
Inhibition of 19S proteasome-associated deubiquitinases by metal-containing compounds. Oncoscience (2015) 0.77
USP14 regulates autophagy by suppressing K63 ubiquitination of Beclin 1. Genes Dev (2016) 0.76
Elevation of proteasomal substrate levels sensitizes cells to apoptosis induced by inhibition of proteasomal deubiquitinases. PLoS One (2014) 0.76
Ubiquitin carboxyl-terminal hydrolase-L5 promotes TGFβ-1 signaling by de-ubiquitinating and stabilizing Smad2/Smad3 in pulmonary fibrosis. Sci Rep (2016) 0.76
An assay for 26S proteasome activity based on fluorescence anisotropy measurements of dye-labeled protein substrates. Anal Biochem (2016) 0.75
Acute lymphoblastic leukemia cells are sensitive to disturbances in protein homeostasis induced by proteasome deubiquitinase inhibition. Oncotarget (2017) 0.75
Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway. J Clin Oncol (2015) 0.75
UCHL1 is a biomarker of aggressive multiple myeloma required for disease progression. Oncotarget (2015) 0.75
Identification of the APC/C co-factor FZR1 as a novel therapeutic target for multiple myeloma. Oncotarget (2016) 0.75
The emerging role of deubiquitinating enzymes in genomic integrity, diseases, and therapeutics. Cell Biosci (2016) 0.75
DUBbing Cancer: Deubiquitylating Enzymes Involved in Epigenetics, DNA Damage and the Cell Cycle As Therapeutic Targets. Front Genet (2016) 0.75
Proteasome-associated deubiquitinase ubiquitin-specific protease 14 regulates prostate cancer proliferation by deubiquitinating and stabilizing androgen receptor. Cell Death Dis (2017) 0.75
The role of deubiquitinases in breast cancer. Cancer Metastasis Rev (2016) 0.75
The proteasome deubiquitinase inhibitor b-AP15 enhances DR5 activation-induced apoptosis through stabilizing DR5. Sci Rep (2017) 0.75
Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells. Clin Cancer Res (2017) 0.75
Meddling with Fate: The Proteasomal Deubiquitinating Enzymes. J Mol Biol (2017) 0.75
Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Oncogene (2017) 0.75
Emerging role of DUBs in tumor metastasis and apoptosis: Therapeutic implication. Pharmacol Ther (2017) 0.75
A novel deubiquitinase inhibitor b-AP15 triggers apoptosis in both androgen receptor-dependent and -independent prostate cancers. Oncotarget (2017) 0.75
Downregulation of ubiquitin-specific protease 14 (USP14) inhibits breast cancer cell proliferation and metastasis, but promotes apoptosis. J Mol Histol (2015) 0.75
Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell (2010) 10.96
p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer (2009) 9.21
Role of Rpn11 metalloprotease in deubiquitination and degradation by the 26S proteasome. Science (2002) 7.49
Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu Rev Biochem (2009) 6.23
Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature (2010) 5.08
Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat Med (2011) 4.09
A novel active site-directed probe specific for deubiquitylating enzymes reveals proteasome association of USP14. EMBO J (2001) 3.42
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell (2005) 3.41
Ubiquitin-mediated activation of TAK1 and IKK. Oncogene (2007) 3.14
Proteasome recruitment and activation of the Uch37 deubiquitinating enzyme by Adrm1. Nat Cell Biol (2006) 3.14
A role for the deubiquitinating enzyme USP28 in control of the DNA-damage response. Cell (2006) 3.10
Structure and mechanisms of the proteasome-associated deubiquitinating enzyme USP14. EMBO J (2005) 2.99
Elimination of cdc2 phosphorylation sites in the cdc25 phosphatase blocks initiation of M-phase. Mol Biol Cell (1993) 2.48
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood (2012) 2.29
Deubiquitinases in cancer: new functions and therapeutic options. Oncogene (2011) 2.08
Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Cancer Res (2010) 2.05
Endoplasmic reticulum stress compromises the ubiquitin-proteasome system. Hum Mol Genet (2005) 1.90
Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell (2013) 1.88
In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res (2011) 1.85
Discovery of specific inhibitors of human USP7/HAUSP deubiquitinating enzyme. Chem Biol (2012) 1.82
CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood (2004) 1.82
A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell (2012) 1.79
DUBs and cancer: the role of deubiquitinating enzymes as oncogenes, non-oncogenes and tumor suppressors. Cell Cycle (2009) 1.77
Deubiquitinating enzymes as novel anticancer targets. Future Oncol (2007) 1.43
The therapeutic potential of deubiquitinating enzyme inhibitors. Biochem Soc Trans (2010) 1.41
The deubiquitinating enzyme UCH37 interacts with Smads and regulates TGF-beta signalling. Oncogene (2005) 1.33
Reverse the curse--the role of deubiquitination in cell cycle control. Curr Opin Cell Biol (2008) 1.31
Proteasome-mediated degradation of cell division cycle 25C and cyclin-dependent kinase 1 in phenethyl isothiocyanate-induced G2-M-phase cell cycle arrest in PC-3 human prostate cancer cells. Mol Cancer Ther (2004) 1.29
AIP1 is critical in transducing IRE1-mediated endoplasmic reticulum stress response. J Biol Chem (2008) 1.27
Arsenite-induced Cdc25C degradation is through the KEN-box and ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A (2002) 1.26
Proteasome deubiquitinases as novel targets for cancer therapy. Int J Biochem Cell Biol (2012) 1.07
Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells. Blood (2012) 1.07
Deubiquitination of CXCR4 by USP14 is critical for both CXCL12-induced CXCR4 degradation and chemotaxis but not ERK ativation. J Biol Chem (2008) 1.06
Ubiquitin-specific protease 14 expression in colorectal cancer is associated with liver and lymph node metastases. Oncol Rep (2006) 1.04
New proteasome inhibitors in myeloma. Curr Hematol Malig Rep (2012) 1.03
Regulators of the proteasome pathway, Uch37 and Rpn13, play distinct roles in mouse development. PLoS One (2010) 1.02
Crystal structure of the catalytic domain of UCHL5, a proteasome-associated human deubiquitinating enzyme, reveals an unproductive form of the enzyme. FEBS J (2011) 0.96
Expression and clinical significance of UCH37 in human esophageal squamous cell carcinoma. Dig Dis Sci (2012) 0.96
Screening for genetic abnormalities involved in ovarian carcinogenesis using retroviral expression libraries. Int J Oncol (2009) 0.84
Whole-genome shotgun assembly and analysis of the genome of Fugu rubripes. Science (2002) 20.59
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med (2003) 16.11
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med (2005) 15.30
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med (2008) 13.06
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
The draft genome of Ciona intestinalis: insights into chordate and vertebrate origins. Science (2002) 11.11
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet (2009) 10.21
A comparison of whole-genome shotgun-derived mouse chromosome 16 and the human genome. Science (2002) 9.59
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell (2005) 7.99
Use of simulated data sets to evaluate the fidelity of metagenomic processing methods. Nat Methods (2007) 7.73
Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med (2012) 6.24
Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc Natl Acad Sci U S A (2007) 6.14
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer (2007) 5.57
Genome sequencing and analysis of the biomass-degrading fungus Trichoderma reesei (syn. Hypocrea jecorina). Nat Biotechnol (2008) 5.38
Induction of functional hepatocyte-like cells from mouse fibroblasts by defined factors. Nature (2011) 5.28
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell (2006) 5.01
NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem (2002) 4.94
Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. Am J Hum Genet (2008) 4.66
Multiple myeloma. Lancet (2009) 4.60
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood (2002) 4.56
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood (2010) 4.52
Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci U S A (2003) 4.47
Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science (2011) 4.46
Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A (2002) 4.33
Patterns and implications of gene gain and loss in the evolution of Prochlorococcus. PLoS Genet (2007) 4.25
Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med (2013) 4.22
Advances in biology of multiple myeloma: clinical applications. Blood (2004) 4.13
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat Med (2011) 4.09
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood (2011) 4.00
Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med (2010) 4.00
Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat Rev Cancer (2009) 3.90
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood (2006) 3.89
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A (2005) 3.86
The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell (2007) 3.76
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood (2002) 3.73
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood (2007) 3.66
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood (2002) 3.62
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol (2006) 3.60
Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol (2009) 3.58
Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn's and colitis epidemiology study. Gastroenterology (2013) 3.55
Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med (2015) 3.47
Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol (2005) 3.43
Legumes symbioses: absence of Nod genes in photosynthetic bradyrhizobia. Science (2007) 3.42
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell (2005) 3.41
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood (2006) 3.39
Neuronal correlates of theory of mind and empathy: a functional magnetic resonance imaging study in a nonverbal task. Neuroimage (2005) 3.38
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood (2009) 3.37
Splicing factor SFRS1 recognizes a functionally diverse landscape of RNA transcripts. Genome Res (2008) 3.33
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A (2003) 3.30
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell (2004) 3.25
Pathogenomic sequence analysis of Bacillus cereus and Bacillus thuringiensis isolates closely related to Bacillus anthracis. J Bacteriol (2006) 3.23
A critical role for the ubiquitin-conjugating enzyme Ubc13 in initiating homologous recombination. Mol Cell (2007) 3.23
Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol (2009) 3.21
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol (2006) 3.20
The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol Mol Biol Rev (2008) 3.16
Dynamic characteristics of blood glucose time series during the course of critical illness: effects of intensive insulin therapy and relative association with mortality. Crit Care Med (2010) 3.16
Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood (2009) 3.12
A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood (2007) 3.09
Quantum-sized carbon dots for bright and colorful photoluminescence. J Am Chem Soc (2006) 3.08
Burkholderia xenovorans LB400 harbors a multi-replicon, 9.73-Mbp genome shaped for versatility. Proc Natl Acad Sci U S A (2006) 3.07
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood (2011) 3.07
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood (2006) 3.04
Tumor stromal architecture can define the intrinsic tumor response to VEGF-targeted therapy. Clin Cancer Res (2013) 3.01
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood (2002) 3.01
Harnessing a high cargo-capacity transposon for genetic applications in vertebrates. PLoS Genet (2006) 2.99
Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease. Neuron (2006) 2.88
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res (2002) 2.83
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood (2007) 2.76
Mechanical strain opens connexin 43 hemichannels in osteocytes: a novel mechanism for the release of prostaglandin. Mol Biol Cell (2005) 2.75
Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica (2006) 2.75
Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med (2006) 2.72
Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene (2002) 2.66
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood (2007) 2.65